natgillin/translations-raw huggingface dataset:
A dedicated study to evaluate the effect of gastric acid-reducing agents on the bioavailability of ceritinib has not been conducted.
Posebno ispitivanje za ocjenjivanje učinka tvari koje smanjuju lučenje želučane kiseline na bioraspoloživost ceritiniba nije provedeno.
A definitive mechanism of action of peginterferon beta-1a in multiple sclerosis (MS) is not known.
Točan mehanizam djelovanja peginterferona beta-1a u multiploj sklerozi (MS) nije poznat.
a degenerative disease of the brain (encephalopathy)
degenerativna bolest mozga (encefalopatija)
a delay in menstrual periods, breast enlargement
kašnjanje menstruacije, povećanje dojki
a deltoid injection as soon as possible at the 100 mg dose
injekcija u deltoidni mišić što je prije moguće, u dozi od 100 mg
a deltoid injection as soon as possible at the same dose the patient was previously stabilised on
injekcija u deltoidni mišić što je prije moguće u istoj dozi na kojoj je bolesnik bio prethodno stabiliziran
a deltoid injection as soon as possible,
injekcija u deltoidni mišić što je prije moguće,
A demonstrable improvement of postprandial CM metabolism was shown in 5/5 patients up to week 14 and in 3/3 patients who were followed up to 52 weeks.
Dokazivo poboljšanje u postprandijalnom metabolizmu hilomikrona pokazalo se kod 5/5 bolesnika do 14. tjedna i kod 3/3 bolesnika, koji su praćeni 52 tjedna.
A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphoshonates in patients with concomitant risk factors.
Prije početka liječenja bisfosfonatima, u bolesnika s istodobnim rizičnim faktorima, preporučuje se stomatološki pregled uz obavljanje preventivnih stomatoloških zahvata i procjena individualne koristi i rizika.
A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, anti-angiogenic medicinal products, corticosteroids, poor oral hygiene).
Prije liječenja bisfosfonatima u bolesnika s istovremeno prisutnim rizičnim faktorima (primjerice rak, kemoterapija, antiangiogeni lijekovi, kortikosteroidi, loša zubna higijena) potrebno je razmotriti potrebu za stomatološkim pregledom i odgovarajućim dentalnim preventivnim zahvatima.
A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene).
U bolesnika s pridruženim faktorima rizika (npr. rak, kemoterapija, radioterapija, kortikosteroidi, loša higijena usne šupljine) preporučuje se pregled zuba i odgovarajući preventivni dentalni zahvati prije liječenja bisfosfonatima.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with Prolia in patients with concomitant risk factors.
Bolesnicima koji imaju prateće faktore rizika preporučuje se stomatološki pregled prije terapije lijekom Prolia te provođenje preventivnih stomatoloških zahvata i individualna procjena koristi i rizika.
A dental examination with preventive dentistry and an individual benefit- risk assessment is recommended prior to treatment with XGEVA.
Prije liječenja lijekom XGEVA preporuča se obaviti stomatološki pregled s preventivnim stomatološkim liječenjem i individualnu procjenu koristi i rizika.
A dental examination with preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with Zoledronic Acid Hospira in patients with concomitant risk factors.
Prije početka liječenja Zolendronatnom kiselinom Hospira, u bolesnika s istodobnim čimbenicima rizika, preporučuje se stomatološki pregled uz obavljanje odgovarajućih preventivnih stomatoloških zahvata i individualna procjena koristi i rizika.
a Derived from a stratified proportional hazards model. b P-value is derived from a log-rank test stratified by prior maintenance therapy and line of therapy; the corresponding O’Brien-Fleming efficacy boundary significance level is 0.0408.
a Dobiveno iz stratificiranog modela proporcionalnih hazarda. b P-vrijednost dobivena je iz log-rang testa stratificiranog prema prethodnoj terapiji održavanja i liniji terapije; odgovarajuća razina značajnosti za granicu djelotvornosti prema O’Brien-Flemingovoj metodi iznosi 0,0408.
A description of the important risks associated with the use of IMLYGIC;
Opis važnih rizika povezanih s primjenom lijeka IMLYGIC;
A description of the risks associated with the use of LEMTRADA namely:
Opis rizika povezanih s primjenom lijeka LEMTRADA, posebice:
A description of the sign and symptoms of autoimmune risks
Opis znakova i simptoma autoimunih rizika
a detailed description of:
detaljni opis:
A developmental NOAEL was not identified.
Razvojni NOAEL nije bi utvrđen.
A diagnosis of lactic acidosis must be considered in the event of non-specific symptoms such as muscle cramps and/or abdominal pain and/or severe asthenia.
Dijagnozu laktacidoze treba razmotriti ako se pojave nespecifični simptomi poput grčeva u mišićima i/ili bol u abdomenu i/ili teška astenija.
A diagnosis of PML should be considered in any Arzerra patient who reports the new onset of or changes in pre-existing neurologic signs and symptoms.
Dijagnozu PML treba razmotriti u svakog bolesnika koji dobiva lijek Arzerra i prijavi pojavu novih ili promjene već postojećih neuroloških znakova i simptoma.
A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI).
potvrdu dijagnoze PRES-a potrebno je oslikavanje mozga, po mogućnosti magnetska rezonancija (MRI).
A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain.
Dijagnozu rupture slezene potrebno je razmotriti u darivatelja i/ili bolesnika koji naovde bol u gornjem lijevom dijelu abdomena ili bol u ramenu.
A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain.
Dijagnozu rupture slezene treba uzeti u obzir u davatelja i/ili bolesnika koji se žale na bol u lijevom gornjem abdomenu i bol u vrhu ramena.
A diagnosis of splenic rupture should be considered in donors and/or patients reporting left upper abdominal pain or shoulder tip pain.
Mogućnost rupture slezene valja uzeti u obzir u davatelja i/ili bolesnika koji se potuže na bol u lijevom gornjem dijelu abdomena ili vrhu ramena.
A dietary recommendation to reduce sodium intake should be carefully considered in the management of patients with heart failure, hypertension or compromised renal function (see section 4.2).
Preporučuje se pažljivo razmotriti preporuku za smanjenje unosa natrija hranom u bolesnika sa zatajenjem srca, hipertenzijom ili oštećenjem funkcije bubrega (vidjeti dio 4.2).
A difference in the frequency of local and general solicited adverse reactions between half adult and adult doses was observed after each dose.
Nakon svake doze zamijećena je razlika u učestalosti lokalnih i općih praćenih nuspojava između pune i pola doze za odrasle.
A different dose may be given to patients with kidney problems.
Pacijenti s bolesnim bubrezima mogu primati drugačiju dozu.
A different scleral site should be used for subsequent injections.
Za svaku sljedeću injekciju treba promijeniti mjesto uboda na bjeloočnici.
a different type of leukaemia to that being treated ulcers in the intestines
leukemija različitog tipa od one koja se liječi čirevi na crijevima
a disease affecting the eardrum and hearing (otosclerosis)
bolest koja utječe na bubnjić uha i sluh (otoskleroza)
A disease affecting the gut which can result in fever, vomiting and stomach pain (diverticulitis).
bolest koja zahvaća crijeva što može dovesti do vrućice, povraćanja i bolova u trbuhu (divertikulitis)
A disease causing muscle weakness and fatigue called myasthenia gravis.
bolest koja uzrokuje mišićnu slabost i umor, a koja se naziva mijastenija gravis.
a disease of the heart valves
bolest srčanih zalistaka
a disease of the stomach or bowel a serious infection (such as pneumonia)
bolest želuca ili crijeva ozbiljnu upalu (kao što je upala pluća).
A disorder characterised by a sudden compelling urge to urinate (micturition urgency), abnormally frequent urination, painful urination
poremećaj karakteriziran naglim neodoljivim nagonom za mokrenjem (hitnost mokrenja), nenormalno često mokrenje, bolno mokrenje
A disorder in which the body’s immune system attacks part of the peripheral nervous system
poremećaj u kojem imunosni sustav tijela napada dio perifernog živčanog sustava
A disorder in which the body’s immune system attacks part of the peripheral nervous system
poremećaj u kojem obrambeni sustav tijela napada dio perifernog živčanog sustava
A disorder of the muscles and nerves in the intestine which causes an obstruction or blockage (pseudo-obstruction)
Poremećaj mišića i živaca crijeva koji uzrokuje opstrukciju ili blokadu (pseudoopstrukcija)
A disruption or early ending of treatment with INCRELEX may impair the success of the growth therapy.
Prekid ili rani prestanak liječenja INCRELEXOM može umanjiti uspjeh terapije rasta.
A doctor experienced in the use of anti-cancer medicines will supervise your Lartruvo therapy.
Terapiju lijekom Lartruvo nadzirat će liječnik s iskustvom u primjeni lijekova za liječenje raka.
A doctor experienced in the use of anti-cancer medicines will supervise your Portrazza therapy.
Terapiju lijekom Portrazza nadzirat će liječnik s iskustvom u primjeni lijekova za liječenje raka.
A doctor or a nurse applies the transdermal system to the patient’s skin on the chest or upper arm.
Liječnik ili medicinska sestra primjenjuju transdermalni sustav na kožu bolesnika na prsa ili nadlakticu.
A doctor or a nurse will administer you Levetiracetam Hospira as an intravenous infusion.
Levetiracetam Hospira vam može dati liječnik ili medicinska sestra u obliku intravenske infuzije.
A doctor or a nurse will give you the medicine as an infusion into a vein (a drip) in hospital.
Lijek će Vam primijeniti liječnik ili medicinska sestra u obliku intravenske infuzije (dripom) u bolnici.
A doctor or nurse will give you a suitable dose of Atriance as an infusion (a drip).
Liječnik ili medicinska sestra dat će Vam odgovarajuću dozu lijeka Atriance u obliku infuzije (drip).
A doctor or nurse will give you this diluted Avastin solution by intravenous infusion (a drip into your vein).
Liječnik ili medicinska sestra će Vam tu razrijeđenu otopinu lijeka Avastin dati infuzijom u venu (kapanjem u venu).
A doctor or nurse will give you your dose of topotecan as an infusion (a drip).
Liječnik ili medicinska sestra dat će Vam odgovarajuću dozu topotekana u obliku infuzije.
A doctor or nurse will give you/your child (if he/she is being treated) a suitable dose of Atriance as an infusion (a drip).
Liječnik ili medicinska sestra dat će Vam/Vašem djetetu (ukoliko se ono liječi) odgovarajuću dozu lijeka Atriance u obliku infuzije (drip).
A doctor or nurse will normally inject Aloxi about 30 minutes before the start of chemotherapy.
Liječnik ili medicinska sestra će Vam ubrizgati Aloxi otprilike 30 minuta prije početka kemoterapije.
A doctor should regularly test the patient’s blood glucose to find the lowest effective dose.
Liječnik treba redovito testirati glukozu u bolesnikovoj krvi kako bi se odredila najniža djelotvorna doza.
A doctor’s assessment of your readiness for treatment will guide the timing of your first Suboxone dose.
Liječnička procjena Vaše spremnosti za liječenje odredit će vrijeme kada ćete uzeti prvu dozu lijeka Suboxone.
A dose (0.5 ml) of the vaccine and a second dose of 0.5 ml at least three weeks later.
Doza (0,5 ml) cjepiva i druga doza od 0,5 ml najmanje tri tjedna kasnije.
A dose (0.5 ml) of the vaccine will be injected into the upper arm (deltoid muscle)
Doza (0,5 ml) cjepiva injicira se u nadlakticu (deltoidni mišić).
A dose adjustment is required for patients with severe renal impairment (creatinine clearance
Prilagodba doze potrebna je za bolesnike s teškim oštećenjem funkcije bubrega (klirens kreatinina
A dose adjustment of the concomitantly administered medicinal product may need to be considered.
Možda će trebati razmotriti prilagodbu doze istovremeno primijenjenog drugog lijeka.
A dose containing 1 g of ceftolozane and 0.5 g of tazobactam is given by infusion over 1 hour every eight hours for 4 to 14 days, depending on the infection being treated and how it responds to the medicine.
Doza koja sadrži 1 g ceftolozana i 0,5 g tazobaktama primjenjuje se infuzijom tijekom 1 sata svakih osam sati tijekom 4 do 14 dana, ovisno o infekciji koja se liječi i odgovoru iste na lijek.
A dose decrease may be needed for
Može biti potrebno smanjenje doze za te
A dose increase of 200 mg/day every 7 to 28 days may be considered if urinary free cortisol and/or plasma cortisol levels are above the normal range, as long as the dose is tolerated by the patient;
Može se razmotriti povećanje doze od 200 mg/dan svakih 7 do 28 dana ako su razine slobodnog kortizola u mokraći i/ili razine kortizola u plazmi iznad normalnog raspona sve dok bolesnik podnosi dozu;
A dose increase of indinavir
Ako se primjenjuje s
A dose increase to the maximum daily dose of 2.5 mg three times daily may be required in patients who are smoking or start smoking during treatment (see section 4.5 and 5.2).
U bolesnika koji puše ili počnu pušiti tijekom liječenja može biti potrebno povisiti dozu na najvišu dnevnu od 2,5 mg tri puta na dan (vidjeti dijelove 4.5 i 5.2).
A dose of 0.035 mg/kg body weight per day (1 mg/m2 body surface area per day) is usually recommended until final height is reached (see section 5.1).
Obično se preporučuje doza od 0,035 mg/kg tjelesne težine na dan (1 mg/m2 tjelesne površine na dan) do postizanja konačne visine (vidjeti dio 5.1).
A dose of 0.045 - 0.050 mg/kg body weight per day (1.4 mg/m2 body surface area per day) is recommended.
Preporučuje se doza od 0,045 - 0,050 mg/kg tjelesne težine na dan (1,4 mg/m2 tjelesne površine na dan).
A dose of 0.5 ml is withdrawn using a syringe for injection
Dozu od 0,5 ml izvući sa štrcaljkom
A dose of 10 mg ketamine/ kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Istodobna primjena doze od 10 mg ketamina/kg s 40 mikrograma deksmedetomidina/kg može uzrokovati tahikardiju.
A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Istodobna primjena 10 mg ketamina/kg i 40 mikrograma deksmedetomidina/kg može uzrokovati tahikardiju.
A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Istodobna primjena doze od 10 mg ketamina/kg i 40 mikrograma deksmedetomidina/kg može uzrokovati tahikardiju.
A dose of 1000 Units (two vials) of Cinryze should be injected at the first sign of a swelling attack.
Dozu od 1000 jedinica (dvije bočice) lijeka Cinryze treba ubrizgati kod prvog znaka oticanja.
A dose of 1000 Units (two vials) of Cinryze should be injected every 3 or 4 days for routine prevention of swelling attacks.
Za rutinsko sprječavanje naglog oticanja dozu od 1000 jedinica (dvije bočice) lijeka Cinryze treba ubrizgavati svaka 3 ili 4 dana.
A dose of 1000 Units (two vials) of Cinryze should be injected up to 24 hours before a medical, dental, or surgical procedure.
Dozu od 1000 jedinica (dvije bočice) lijeka Cinryze treba ubrizgati do 24 sata prije medicinskog, zubarskog ili kirurškog zahvata.
A dose of 150 mg daily must not be exceeded.
Ne smije se prekoračiti doza od 150 mg eltrombopaga dnevno.
A dose of 150 mg is recommended:
Preporučena doza je 150 mg:
A dose of 20 ml oral suspension (10 g glycerol) or more may cause headache, stomach upset and diarrhoea.
Doza od 20 ml oralne suspenzije (10 g glicerola) ili viša može uzrokovati glavobolju, nadražen želudac i proljev.
A dose of 2000 IU Coagadex administered to a 70 kg patient should be expected to result in a peak post-infusion factor X increase of 2000 x {[2 IU/dL]/[IU/kg]}/[70 kg] = 57 IU/dL (i.e.
Očekuje se da će doza od 2000 IU lijeka Coagadex primijenjena bolesniku od 70 kg nakon infuzije rezultirati vršnim porastom faktora X od 2000 x {[2 IU/dl]/[IU/kg]}/[70 kg] = 57 IU/dl (tj.
A dose of 220 mg taken as one 110 mg capsule twice daily can be individually considered, at the discretion of the physician, when the thromboembolic risk is low and the bleeding risk is high (see section 4.4).
Može se razmotriti doza od 220 mg u obliku jedne kapsule od 110 mg dvaput dnevno u pojedinačnim slučajevima, prema odluci liječnika, kada je rizik tromboembolije nizak, a rizik od krvarenja visok (vidjeti dio 4.4).
A dose of 23 mg sodium is considered essentially ‘sodium-free’.
Smatra se da je doza od 23 mg natrija zanemariva količina natrija.
A dose of 25 IU r-hLH daily (in combination with 150 IU follitropin alfa) resulted in insufficient follicular development.
Dnevna doza od 25 IU r-hLH (u kombinaciji sa 150 IU folitropina alfa) rezultirala je nedovoljnim razvojem folikula.
A dose of 3.2 mg/kg intravenously (approximately 8 times the therapeutic dose) caused transient erythema, itching or hypotension in healthy subjects.
Doza od 3,2 mg/kg primijenjena intravenski (otprilike 8 puta terapijska doza) uzrokovala je prolazni eritem, svrbež ili hipotenziju kod zdravih ispitanika.
A dose of 300 mg/kg/day to rats was associated with a ceftolozane plasma exposure (AUC) value approximately equivalent to the ceftolozane plasma AUC value at the human therapeutic dose.
U štakora je doza od 300 mg/kg/dan bila povezana s vrijednošću izloženosti ceftolozanu u plazmi (AUC) koja je bila približno ekvivalentna vrijednosti AUC-a ceftolozana u plazmi kod terapijskih doza u ljudi.
A dose of 600 IU/kg body weight should be administered once weekly for three weeks (on day 21, 14 and 7) prior to surgery and on the day of surgery (day 0).
Potrebno je dati dozu od 600 IU/kg tjelesne težine jedanput tjedno tijekom tri tjedna (na dan 21, 14 i 7) prije operacije i na sam dan operacije (dan 0).
A dose of 600 IU/kg is given by injection under the skin once weekly for 3 weeks before surgery and on the day of surgery.
Doza od 600 IU/kg daje se injekcijom pod kožu jedanput tjedno tijekom 3 tjedna prije operacije i na dan operacije.
A dose of 75 IU r-hLH daily (in combination with 150 IU follitropin alfa (r-hFSH)) resulted in adequate follicular development and oestrogen production.
Dnevna doza od 75 IU r-hLH-a (u kombinaciji sa 150 IU folitropina alfa (r-hFSH)) rezultirala je odgovarajućim razvojem folikula i stvaranjem estrogena.
A dose of 85 mg is recommended:
Preporučena doza je 85 mg:
A dose reduction is recommended for ITP patients with platelet counts between 150,000-250,000/μl.
Preporučuje se smanjenje doze ITP bolesnicima s brojem trombocita između
A dose reduction is recommended in patients with mildly or moderately reduced liver function, whereas Imbruvica is not recommended in patients with severely reduced liver function.
Smanjenje doze preporuča se u bolesnika s blagim do umjerenim oštećenjem funkcije jetre, pri čemu se lijek Imbruvica ne preporuča u bolesnika s ozbiljnim oštećenjem jetre.
A dose reduction may be required (see section 4.2).
Može biti potrebno smanjenje doze (vidjeti dio 4.2).
A dose reduction may be required (see section 4.2).
Može biti potrebno smanjenje doze lenalidomida (vidjeti dio 4.2).
A dose reduction of abacavir may be required for patients with mild hepatic impairment (Child-Pugh grade A).
Možda će trebati smanjiti dozu abakavira u bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh stadij A).
A dose reduction of clarithromycin
Smanjenje doze klaritromicina može
A dose reduction of ketoconazole should be considered when co- administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer. (See also “Effects of other medicinal products on the metabolism of Ketoconazole HRA ”).
Treba razmotriti smanjenje doze ketokonazola kada se primjenjuje istovremeno s ritonavirom u dozi antiretrovirusnog lijeka ili farmakokinetičkog pojačivača. (Vidjeti također „Učinci drugih lijekova na metabolizam Ketoconazolea HRA”).
A dose reduction of Myocet has been shown to be appropriate in patients with impaired hepatic function (see section 4.2 for dosage recommendations).
Smanjenje doze Myoceta pokazalo se odgovarajućim u bolesnika s oštećenjem jetrene funkcije (vidjeti dio 4.2 za preporuke o doziranju).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid which is not a substrate for CYP3A (e.g., beclomethasone).
Mora se razmotriti smanjenje doze glukokortikosteroida uz pomno praćenje lokalnih i sistemskih učinaka ili prebacivanje na liječenje s glukokortikosteroidima koji nisu supstrati za CYP3A (npr. beklometazon).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (eg, beclomethasone).
Valja razmotriti smanjivanje doze glukokortikoida i pažljivo pratiti lokalne i sistemne učinke, ili prijeći na primjenu glukokortikoida koji nije supstrat enzima CYP3A4 (npr. beklometazon).
A dose related but moderate compensatory physiological hypertrophy of the zona glomerulosa of the adrenal glands was also observed at doses of 3 times and greater of the recommended dose.
Umjerena, kompenzatorna fiziološka hipertrofija zone glomerulose nadbubrežne žlijezde povezana s dozom također je uočena pri dozama tri puta većim od preporučene doze.
A dose response was seen; results with 10 mg were intermediate between placebo and 25 mg.
Primijećen je odgovor ovisan o dozi; rezultati u bolesnika koji su primali 10 mg bili su negdje između onih zabilježenih u skupine koja je uzimala placebo i skupine koja je uzimala dozu od 25 mg.
A dose to treat a breakthrough pain episode might be either 1 spray or 2 sprays (one in each nostril).
Doza za liječenje epizode probijajuće boli može biti 1 potisak (raspršivanje) ili 2 potiska (po jedno raspršivanje u svaku nosnicu).
A dose- relationship of adverse reaction was not established and they showed no correlation with gender, age or race of the patients.
Utjecaj doza na nuspojave nije utvrđen, te one nisu pokazale korelaciju sa spolom, dobi ili rasom bolesnika.
A dose- relationship of adverse reactions was not established and they showed no correlation with gender, age or race of the patients.
Utjecaj doza na nuspojave nije utvrđen te one nisu pokazale korelaciju sa spolom, dobi ili rasom bolesnika.
A dose-adjustment may be necessary for substances metabolised by CYP2D6 and that are individually dose titrated.
Može biti neophodna prilagodba doza za tvari koje metabolizira CYP2D6 i čija se doza individualno titrira.
A dose-dependent increase in heart rate was also observed.
Primijećeno je i o dozi ovisno ubrzanje srčanog ritma.
A dose-relationship of adverse reactions was not established and they showed no correlation with gender, age or race of the patients.
Utjecaj doza na nuspojave nije utvrđen, te one nisu pokazale korelaciju sa spolom, dobi ili rasom bolesnika.
A dosing spoon is provided to measure small doses below 4g for young children.
S lijekom se isporučuje i žlica za doziranje kako bi se omogućilo mjerenje doza manjih od 4g za mlađu djecu.
A double dose should not be given to make up for a forgotten dose.
Ne smije se primijeniti dvostruka doza kako bi se nadoknadila zaboravljena doza.
A double dose should not be taken in the same day.
Dvostruka se doza ne smije uzeti istog dana,
A double-blind randomised dose comparison study of 802 relapsing MS patients (AVONEX 30 micrograms n=402, AVONEX 60 micrograms n=400) has shown no statistically significant differences or trends between the 30 micrograms and the 60 micrograms doses of AVONEX in clinical and general MRI parameters.
Dvostruko slijepo ispitivanje uspoređivanja randomiziranih doza na 802 bolesnika s relapsirajućom MS-om (AVONEX, 30 mikrograma n=402, AVONEX, 60 mikrograma n=400) nije pokazala statistički značajne razlike između ddoza Avonexa od 30 mikrograma i 60 mikrograma u kliničkim i općim MRI parametrima.